TY - JOUR
T1 - Prognostic Value of Preoperative Nutritional and Immunological Factors in Patients with Pancreatic Ductal Adenocarcinoma
AU - Abe, Toshiya
AU - Nakata, Kohei
AU - Kibe, Shin
AU - Mori, Yasuhisa
AU - Miyasaka, Yoshihiro
AU - Ohuchida, Kenoki
AU - Takao, Ohtsuka
AU - Oda, Yoshinao
AU - Nakamura, Masafumi
N1 - Funding Information:
ACKNOWLEDGMENT This work was supported in part by a Japan Society for the Promotion of Science Grant-in-Aid for Fellows (No. 16J03962), Scientific Research (B) [Nos. 17H04284, 16H05417, 16H05418] and (C) [No. 16K10601], and Scientific Research on Innovative Areas (Nos. 17K19602, 17K19605). The authors thank Mary Derry, Ph.D. ELS, from Edanz Group (www.edanzediting.c om/ac) for editing a draft of this manuscript.
Publisher Copyright:
© 2018, Society of Surgical Oncology.
PY - 2018/12/1
Y1 - 2018/12/1
N2 - Background: Preoperative nutritional and immunological patient factors have been found to be associated with prognostic outcomes of malignant tumors; however, the clinical significance of these factors in pancreatic ductal adenocarcinoma (PDAC) remains controversial. Objective: The aim of this study was to evaluate the prognostic value of nutritional and immunological factors in predicting survival of patients with PDAC. Methods: Retrospective studies of 329 patients who underwent surgical resection for PDAC and 95 patients who underwent palliative surgery were separately conducted to investigate the prognostic impact of tumor-related factors and patient-related factors, including Glasgow Prognostic Score (GPS), modified GPS, Prognostic Nutritional Index (PNI), neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio, and lymphocyte/monocyte ratio. Results: In multivariate analysis for patients with surgical resection for PDAC, PNI was an independent factor for overall survival (OS) and disease-free survival. The median OS of patients with PNI ≤ 45 was significantly shorter than that of patients with PNI > 45 (17.5 and 36.2 months, respectively; p < 0.001). In multivariate analysis for patients undergoing palliative surgery for PDAC, only NLR was an independent prognosis factor. The median OS of patients with NLR > 5 was significantly shorter than that of patients with NLR ≤ 5 (2.7 and 8.9 months, respectively; p < 0.001). Conclusions: PNI in patients with surgical resection and NLR in patients with palliative surgery for PDAC may be useful prognostic factors.
AB - Background: Preoperative nutritional and immunological patient factors have been found to be associated with prognostic outcomes of malignant tumors; however, the clinical significance of these factors in pancreatic ductal adenocarcinoma (PDAC) remains controversial. Objective: The aim of this study was to evaluate the prognostic value of nutritional and immunological factors in predicting survival of patients with PDAC. Methods: Retrospective studies of 329 patients who underwent surgical resection for PDAC and 95 patients who underwent palliative surgery were separately conducted to investigate the prognostic impact of tumor-related factors and patient-related factors, including Glasgow Prognostic Score (GPS), modified GPS, Prognostic Nutritional Index (PNI), neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio, and lymphocyte/monocyte ratio. Results: In multivariate analysis for patients with surgical resection for PDAC, PNI was an independent factor for overall survival (OS) and disease-free survival. The median OS of patients with PNI ≤ 45 was significantly shorter than that of patients with PNI > 45 (17.5 and 36.2 months, respectively; p < 0.001). In multivariate analysis for patients undergoing palliative surgery for PDAC, only NLR was an independent prognosis factor. The median OS of patients with NLR > 5 was significantly shorter than that of patients with NLR ≤ 5 (2.7 and 8.9 months, respectively; p < 0.001). Conclusions: PNI in patients with surgical resection and NLR in patients with palliative surgery for PDAC may be useful prognostic factors.
UR - http://www.scopus.com/inward/record.url?scp=85053515090&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053515090&partnerID=8YFLogxK
U2 - 10.1245/s10434-018-6761-6
DO - 10.1245/s10434-018-6761-6
M3 - Article
C2 - 30225838
AN - SCOPUS:85053515090
SN - 1068-9265
VL - 25
SP - 3996
EP - 4003
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 13
ER -